Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle

The muscle myosins are hexomeric proteins consisting of two heavy chains and two pairs of light chains, the latter called essential (ELC) and regulatory (RLC). The light chains stabilize the long alpha helical neck of the myosin head. Their function in striated muscle, however, is only partially understood. We report here the identification of distinct missense mutations in a skeletal/ventricular ELC and RLC, each of which are associated with a rare variant of cardiac hypertrophy as well as abnormal skeletal muscle.We show that myosin containing the mutant ELC has abnormal function, map the mutant residues on the three–dimensional structure of myosin and suggest that the mutations disrupt the stretch activation response of the cardiac papillary muscles.

[1]  A. Huxley.  Muscle structure and theories of contraction. , 1957, Progress in biophysics and biophysical chemistry.

[2]  H E Huxley,et al.  The Mechanism of Muscular Contraction , 1965, Scientific American.

[3]  A. Huxley,et al.  Proposed Mechanism of Force Generation in Striated Muscle , 1971, Nature.

[4]  E. Eisenberg,et al.  Troponin-tropomyosin complex. Column chromatographic separation and activity of the three, active troponin components with and without tropomyosin present. , 1974, The Journal of biological chemistry.

[5]  J. Pringle.  The Croonian Lecture, 1977 - Stretch activation of muscle: function and mechanism , 1978, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[6]  B. Maron,et al.  Hypertrophic cardiomyopathy: a discussion of nomenclature. , 1979, The American journal of cardiology.

[7]  E. Eisenberg,et al.  The relation of muscle biochemistry to muscle physiology. , 1980, Annual review of physiology.

[8]  J. Gottdiener,et al.  Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. , 1981, The American journal of cardiology.

[9]  J. Devereux,et al.  A comprehensive set of sequence analysis programs for the VAX , 1984, Nucleic Acids Res..

[10]  G. Lathrop,et al.  Easy calculations of lod scores and genetic risks on small computers. , 1984, American journal of human genetics.

[11]  J. Stull,et al.  The effect of myosin phosphorylation on the contractile properties of skinned rabbit skeletal muscle fibers. , 1985, The Journal of biological chemistry.

[12]  J. Stull,et al.  Phosphorylation of myosin in permeabilized mammalian cardiac and skeletal muscle cells. , 1986, The American journal of physiology.

[13]  J. Rüegg,et al.  Calcium sensitivity of myofilaments in cardiac muscle--effect of myosin phosphorylation. , 1986, Basic research in cardiology.

[14]  I. Trayer,et al.  Evidence that the N-terminal region of A1-light chain of myosin interacts directly with the C-terminal region of actin. A proton magnetic resonance study. , 1987, European journal of biochemistry.

[15]  U. Francke,et al.  Human ventricular/slow twitch myosin alkali light chain gene characterization, sequence, and chromosomal location. , 1989, The Journal of biological chemistry.

[16]  J. Sellers,et al.  Characterization of in vitro motility assays using smooth muscle and cytoplasmic myosins. , 1990, The Journal of biological chemistry.

[17]  M. Whittaker,et al.  Molecular structure of F-actin and location of surface binding sites , 1990, Nature.

[18]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[19]  R. Wadgaonkar,et al.  Localization of the gene coding for ventricular myosin regulatory light chain (MYL2) to human chromosome 12q23-q24.3. , 1992, Genomics.

[20]  A. Marian,et al.  Expression of a missense mutation in the messenger RNA for beta-myosin heavy chain in myocardial tissue in hypertrophic cardiomyopathy. , 1992, The Journal of clinical investigation.

[21]  L. Fananapazir,et al.  Differences in Clinical Expression of Hypertrophic Cardiomyopathy Associated With Two Distinct Mutations in the β‐Myosin Heavy Chain Gene: A 908Leu→Val Mutation and a 403Arg→gGln Mutation , 1992, Circulation.

[22]  M. Dalakas,et al.  Missense mutations in the beta-myosin heavy-chain gene cause central core disease in hypertrophic cardiomyopathy. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D A Winkelmann,et al.  Three-dimensional structure of myosin subfragment-1: a molecular motor. , 1993, Science.

[24]  W. Zhu,et al.  Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. , 1993, The Journal of clinical investigation.

[25]  James A. Spudich,et al.  How molecular motors work , 1994, Nature.

[26]  K. Trybus,et al.  The essential light chain is required for full force production by skeletal muscle myosin. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Fananapazir,et al.  Genotype-Phenotpe Correlations in Hypertrophic Cardiomyopathy Insights Provided by Comparisons of Kindreds With Distinct and Identical j3-Myosin Heavy Chain Gene Mutations , 2005 .

[28]  I. Schlichting,et al.  Structure of the regulatory domain of scallop myosin at 2.8 Ä resolution , 1994, Nature.

[29]  Christine E. Seidman,et al.  α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere , 1994, Cell.

[30]  Giovanni Romeo,et al.  Phenotypic diversity, allelic series and modifier genes , 1994, Nature Genetics.

[31]  Malcolm Irving,et al.  Tilting of the light-chain region of myosin during step length changes and active force generation in skeletal muscle , 1995, Nature.

[32]  Michael Whittaker,et al.  A 35-Å movement of smooth muscle myosin on ADP release , 1995, Nature.

[33]  A. Simcox,et al.  Impairment of muscle function caused by mutations of phosphorylation sites in myosin regulatory light chain , 1995, Nature.

[34]  J. Beckmann,et al.  Cardiac myosin binding protein–C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[35]  A. Fisher,et al.  Structural studies of myosin:nucleotide complexes: a revised model for the molecular basis of muscle contraction. , 1995, Biophysical journal.

[36]  I. Rayment,et al.  Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  L. Fananapazir,et al.  Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. , 1995, The Journal of clinical investigation.

[38]  Myosin Cross-Bridge Elasticity , 1995 .

[39]  J. Seidman,et al.  Mutations in the cardiac myosin binding protein–C gene on chromosome 11 cause familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[40]  A. Houdusse,et al.  Structure of the regulatory domain of scallop myosin at 2 A resolution: implications for regulation. , 1996, Structure.